TY - JOUR
T1 - Targeted delivery systems for molecular therapy in skeletal disorders
AU - Dang, Lei
AU - LIU, Jin
AU - LI, Fangfei
AU - Wang, Luyao
AU - LI, Defang
AU - GUO, Baosheng
AU - He, Xiaojuan
AU - Jiang, Feng
AU - Liang, Chao
AU - Liu, Biao
AU - Badshah, Shaikh Atik
AU - He, Bing
AU - Lu, Jun
AU - Lu, Cheng
AU - Lyu, Aiping
AU - Zhang, Ge
N1 - Funding Information:
We thank the other academic staff members in Aiping Lu and Ge Zhang?s group at Hong Kong Baptist University. We also thank Hong Kong Baptist University for providing critical comments and technical support. This study was supported by the Hong Kong General Research Fund (HKBU12102914 to Ge Zhang) and the Faculty Research Grant of Hong Kong Baptist University (FRG2/12-13/027 to Ge Zhang).
PY - 2016/3/22
Y1 - 2016/3/22
N2 - Abnormalities in the integral components of bone, including bone matrix, bone mineral and bone cells, give rise to complex disturbances of skeletal development, growth and homeostasis. Non-specific drug delivery using high-dose systemic administration may decrease therapeutic efficacy of drugs and increase the risk of toxic effects in non-skeletal tissues, which remain clinical challenges in the treatment of skeletal disorders. Thus, targeted delivery systems are urgently needed to achieve higher drug delivery efficiency, improve therapeutic efficacy in the targeted cells/tissues, and minimize toxicities in non-targeted cells/tissues. In this review, we summarize recent progress in the application of different targeting moieties and nanoparticles for targeted drug delivery in skeletal disorders, and also discuss the advantages, challenges and perspectives in their clinical translation.
AB - Abnormalities in the integral components of bone, including bone matrix, bone mineral and bone cells, give rise to complex disturbances of skeletal development, growth and homeostasis. Non-specific drug delivery using high-dose systemic administration may decrease therapeutic efficacy of drugs and increase the risk of toxic effects in non-skeletal tissues, which remain clinical challenges in the treatment of skeletal disorders. Thus, targeted delivery systems are urgently needed to achieve higher drug delivery efficiency, improve therapeutic efficacy in the targeted cells/tissues, and minimize toxicities in non-targeted cells/tissues. In this review, we summarize recent progress in the application of different targeting moieties and nanoparticles for targeted drug delivery in skeletal disorders, and also discuss the advantages, challenges and perspectives in their clinical translation.
KW - Nanoparticles
KW - Skeletal disorders
KW - Targeted delivery systems
KW - Targeting moieties
UR - http://www.scopus.com/inward/record.url?scp=85006728613&partnerID=8YFLogxK
U2 - 10.3390/ijms17030428
DO - 10.3390/ijms17030428
M3 - Journal article
C2 - 27011176
AN - SCOPUS:85006728613
SN - 1661-6596
VL - 17
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 3
M1 - 428
ER -
